Table 1.
Patient Baseline Characteristics and Rates of H. Pylori Eradication Based on Therapy.
| First-line therapy | Second-line therapy | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eradication rate | Eradication rate | |||||||||||
| All | 1,172 | 86.9 | 157 | 91.1 | ||||||||
| Age, years | 61.0 | [51.0-69.0] | 62.0 | [49.5-70.0] | ||||||||
| ≤39 | 113 | (9.6) | 76.1 | 25 | (15.9) | 96.0 | ||||||
| 40-49 | 141 | (12.0) | 90.8 | * | 14 | (8.9) | 85.7 | |||||
| 50-59 | 287 | (24.5) | 89.9 | ** | 30 | (19.1) | 93.3 | |||||
| 60-69 | 363 | (31.0) | 88.4 | ** | 46 | (29.3) | 97.8 | |||||
| ≥70 | 268 | (22.9) | 84.3 | 42 | (26.8) | 81.0 | ||||||
| Gender | ||||||||||||
| male | 566 | (48.3) | 88.0 | 66 | (42.0) | 93.9 | ||||||
| female | 606 | (51.7) | 86.0 | 91 | (58.0) | 89.0 | ||||||
| Acid suppression drug | ||||||||||||
| esomeprazole | 67 | (5.7) | 85.1 | 10 | (6.4) | 90.0 | ||||||
| lansoprazole | 454 | (38.7) | 84.6 | 55 | (35.3) | 94.5 | ||||||
| rabeprazole | 236 | (20.1) | 82.2 | 43 | (27.6) | 86.0 | ||||||
| vonoprazan | 415 | (35.4) | 92.5 | † | 48 | (30.8) | 93.8 | |||||
| Atrophy | ||||||||||||
| mild | 553 | (47.2) | 87.3 | 71 | (45.2) | 94.4 | ||||||
| severe | 600 | (51.2) | 86.2 | 82 | (52.2) | 87.8 | ||||||
| unknown* | 19 | (1.6) | 4 | (2.5) | ||||||||
| Side effects | 37 | (2.2) | 3 | (1.9) | ||||||||
Values are shown as n (%) or median [IQR]. *Including post-distal gastrectomy state.
Eradication therapy success shown as percentage.
*p<0.05, vs. ≤39 years; **p<0.01, vs. ≤39 years; †p<0.05, vs. lansoprazole and rabeprazole (Steel-Dwass test).